NEW YORK, Jan. 26, 2024 (GLOBE NEWSWIRE) --  FMW Media's New to The Street, a national TV show, announces episode 551, airing on the FOX Business Network on Monday, January 29, 2024, at 10:30 PM PT. New to The Street's 551st episode line-up features the following Five (5) Corporate interviews: 1). Biopharmaceutical -Acurx Pharmaceuticals, Inc.'s (NASDAQ:ACXP) ($ACXP) interview with David Luci, President/CEO. 2). Financial Marketplace Strategies – Blue Castle Ventures LTD's ($BCVD) interviews with David Roja ...

STATEN ISLAND, N.Y., Jan. 23, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. ("Acurx" or the "Company") (NASDAQ: "ACXP"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections, today announced that David P. Luci, President & Chief Executive Officer, will be presenting at The Microcap Conference, which will take place January 30, 2024-February 1, 2024 at the Ceasars Atlantic City Hotel & Casino in Atlantic City, New Jersey. P ...

Core Viewpoint - Acurx Pharmaceuticals' shares experienced a significant decline despite positive data regarding its novel C. diff antibiotic, ibezapolstat, which reportedly outperformed vancomycin in preserving the gut microbiome during treatment [1][11] Share Price Decline Reasons - The decline in share price is not attributed to bad data, as most efficacy data is available; rather, it may stem from misaligned investor expectations regarding the anticipated release of 94-day efficacy data [2] - The company confirmed it did not utilize its ATM facility during the press release, suggesting that the sell-off was not due to capital raising activities [2] Data Release - Acurx's data release was limited to a general success statement, with detailed results reserved for a conference presentation; investors can expect the 94-day sustained clinical cure rates to be released soon [3] - The gut microbiome study may position ibezapolstat as a preferred antibiotic for C. diff treatment [3] C. Difficile Infection Recurrence Rates - Ridinilazole, another C. diff antibiotic, failed a phase 3 trial, showing similar performance to vancomycin but with a lower recurrence rate [4] - Acurx's ibezapolstat demonstrated a 100% clinical cure rate in a small sample, raising questions about the reliability of this data [5] - The microbiome data suggests that ibezapolstat may not be an outlier, but confirmation through the upcoming 94-day data is necessary [5] Phase 3 Trial Considerations - Acurx may benefit from focusing on endpoints that highlight ibezapolstat's strengths, such as gut microbiome preservation, rather than solely on cure rate superiority over vancomycin [7] Upcoming Catalysts - The most significant upcoming catalyst is the confirmation of efficacy through the release of 94-day extended clinical cure rates, which is crucial for investor confidence [8] Financial Overview - Acurx had $7.1 million in cash as of September 2023, with a need for additional funding for a phase 3 trial; the company may have utilized its ATM facility to bolster its cash balance [9] - The company’s market cap is relatively small, raising concerns about its ability to execute licensing deals or avoid dilution [9]

Core Insights - Acurx Pharmaceuticals announced that its lead antibiotic candidate, ibezapolstat, demonstrated superior efficacy compared to vancomycin in eradicating fecal C. difficile in a Phase 2b clinical trial, achieving a 94% eradication rate versus vancomycin's 71% [1][3][6] - Ibezapolstat preserved key gut bacterial species that are believed to help prevent recurrence of Clostridioides difficile infection (CDI), a significant advantage over vancomycin [1][2][11] - The company is preparing for meetings with regulatory agencies and advancing towards international Phase 3 clinical trials, following positive results from the Phase 2b trial [1][3][12] Company Overview - Acurx Pharmaceuticals is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics targeting difficult-to-treat bacterial infections, including CDI [16] - The company’s lead candidate, ibezapolstat, is a Gram-Positive Selective Spectrum (GPSS™) antibiotic that inhibits DNA polymerase IIIC, contributing to its unique mechanism of action [11][16] - Ibezapolstat has received FDA designations such as Qualified Infectious Disease Product (QIDP) and Fast-Track, highlighting its potential in addressing urgent medical needs [12][16] Clinical Trial Insights - The Phase 2b trial involved 32 patients with CDI, randomized to receive either ibezapolstat or vancomycin, with a follow-up period to assess recurrence [6][8] - The overall clinical cure rate for ibezapolstat across both Phase 2 trials was 96%, indicating strong efficacy [6][8] - The trial was discontinued early due to the observed success, allowing for expedited progression to Phase 3 trials [7][8] Market Potential - The U.S. CDI market is estimated to exceed $1 billion, and Acurx anticipates that ibezapolstat could be competitively priced compared to existing antibiotics [3][12] - The company aims to leverage its clinical data to differentiate ibezapolstat in the market, focusing on both efficacy and microbiome health [3][12] Future Developments - Further analyses from the Phase 2b trial, including Extended Clinical Cure (ECC) data, are expected in Q1 2024 [1][2] - Acurx is preparing for an end of Phase 2 meeting with the FDA, targeted for the second quarter of 2024, to discuss the next steps for ibezapolstat [2][3]

NEW YORK, Jan. 05, 2024 (GLOBE NEWSWIRE) -- FMW Media's New to The Street, a nationally broadcasted TV show, announces episode 543, airing on the Fox Business Network, Monday, January 8, 2024, at 10:30 PM PT. New to The Street's 543rd TV episode line-up features the following four (4) Corporate interviews: 1). Biopharmaceutical – Acurx Pharmaceuticals, Inc.'s (NASDAQ:ACXP) ($ACXP) interview with David Luci, President/CEO. 2). "Game Changers Segment" interview with Dr. Navjit Dhaliwal, CEO, IAGON (CRYPTO: IA ...

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q3 2023 Earnings Conference Call November 14, 2023 8:00 AM ET Company Participants Robert Shawah - CFO David Luci - President & CEO Robert DeLuccia - Executive Chairman Conference Call Participants Michael Okunewitch - Maxim Group Thomas Yip - H.C. Wainwright James Molloy - Alliance Global Partners Operator Ladies and gentlemen, good morning, and welcome to the Acurx Pharmaceuticals Third Quarter 2023 Earnings Conference Call. At this time, all participants are in a ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended September 30, 2023 Or ☐ Transition Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 001-40536 Acurx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 82-3733567 State or other jurisdiction of (I.R.S. Employer incorporation ...

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q2 2023 Earnings Conference Call August 14, 2023 8:00 AM ET Company Participants Rob Shawah - CFO Dave Luci - President and CEO Conference Call Participants Ed Arce - HC. Wainwright Michael Okunewitch - Maxim Group Jim Molloy - Alliance Global Partners Operator Greetings, and welcome to the Acurx Pharmaceuticals to discuss Second Quarter 2023 Financial Results and Business Update. At this time, all participants are in a listen-only mode. A brief question and answer ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended June 30, 2023 Or ☐ Transition Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 001-40536 Acurx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 82-3733567 State or other jurisdiction of (I.R.S. Employer incorporation or o ...

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q1 2023 Earnings Conference Call May 12, 2023 8:00 AM ET Company Participants Rob Shawah - CFO Dave Luci - President and CEO Conference Call Participants Jim Molloy - Alliance Global Partners Operator Greetings, and welcome to the Acurx Pharmaceuticals First Quarter 2023 Financial Results and Business Update. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Rob Shawah, Chief Financial Officer. Th ...